ClinicalTrials.gg
CompletedNCT02524626Updated Feb 10, 2023

Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve

A Phase 3 interventional study of Sham stimulation and Vagus stimulation in Postoperative Ileus, sponsored by KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by KU Leuven · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hypothesis:

Electrical stimulation of the abdominal vagus nerve has anti-inflammatory effects which lead to a faster postoperative recovery after abdominal surgery.

Aims:

In the present study, the investigators want evaluate the anti-inflammatory effect of peroperative electrical stimulation of the vagus nerve. In addition, the investigators want to determine whether vagus nerve stimulation leads to a faster postoperative recovery. To this end, the following aims are formulated:

  1. to determine whether vagus nerve stimulation leads to an improvement in gastrointestinal transit using radiological testing
  2. to evaluate whether electrical stimulation of the vagus nerve leads to clinical improvement (daily questionnaire)
  3. to show that electrical stimulation of the intra-abdominal vagus nerve reduces the inflammatory response to abdominal surgery
02

Conditions studied

  • Postoperative Ileus

Browse trials for

Keywords

  • Vagus nerve stimulation
  • Postoperative ileus
03

In context

Ileus

167 studies on the registry are indexed under Ileus; 23 are open to participants now.

This study's enrollment of 130 is above the median of 90 across 138 interventional studies indexed under Ileus.

Browse Ileus studies →

Lead sponsor

KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with ovarium, pancreas or colorectal carcinoma eligible for resection

Exclusion criteria

Exclusion Criteria:

  • preoperative therapeutic abdominal radiation shorter than 2 weeks prior to surgery
  • evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory test results, including abscess or cholecystitis)
  • physical-health status classification (ASA-PS) > 3
  • poorly regulated diabetes (> 200 mg/dl (= 11 mmol/l)
  • surgery due to chronic pancreatitis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Sham comparator
    Sham stimulation

    no stimulation of vagus nerve

    Procedure: Sham stimulation

  • Active comparator
    Vagus stimulation

    Stimulation of the vagus nerve at the beginning and the end of the surgery

    Procedure: Vagus stimulation

Interventions

  • ProcedureSham stimulation

    Sham stimulation

  • ProcedureVagus stimulation

    Vagus stimulation

06

What researchers measure

Primary outcomes

  1. The gastrointestinal transit (geometric mean)

    Time frame: From postoperative day 3 until postoperative day 7

Secondary outcomes

  1. Gastric stasis (volume of gastric fluid produced by gastric tube on postoperative day 1

    Time frame: From the date of surgery until postoperative day 1

  2. Time to first flatus

    Time frame: From the date of surgery until the date of discharge from the hospital (on average 14 days)

  3. Time to tolerance of oral food intake

    Time frame: From the date of surgery until the date of discharge from the hospital (on average 14 days)

  4. Time to tolerance of oral food intake and first defecation

    Time frame: From the date of surgery until the date of discharge from the hospital (on average 14 days)

  5. Time to first defecation

    Time frame: From the date of surgery until the date of discharge from the hospital (on average 14 days)

  6. Gastrointestinal symptoms (nausea, pain, vomiting, bloating)

    Time frame: From the date of surgery until the date of discharge from the hospital (on average 14 days)

  7. Time to discharge from the hospital

    Time frame: From the date of surgery until the date of discharge from the hospital (on average 14 days)

  8. Levels of pro-inflammatory cytokines in intestinal tissue, serum, peritoneal lavage and supernatant of stimulated whole blood

    Time frame: From the date of surgery until the date of lab analysis (up to 6 months)

07

Study locations

1 site
  • University Hospitals Leuven
    Leuven, 3000, Belgium
08

References and documents

Publications

  • Kalff JC, Buchholz BM, Eskandari MK, Hierholzer C, Schraut WH, Simmons RL, Bauer AJ. Biphasic response to gut manipulation and temporal correlation of cellular infiltrates and muscle dysfunction in rat. Surgery. 1999 Sep;126(3):498-509. PubMed 10486602 ↗
  • Kalff JC, Schraut WH, Simmons RL, Bauer AJ. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg. 1998 Nov;228(5):652-63. doi: 10.1097/00000658-199811000-00004. PubMed 9833803 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02524626
Lead sponsor
KU Leuven
Responsible party
Guy Boeckxstaens (Principal Investigator, KU Leuven) — Principal investigator
First posted
Aug 17, 2015
Start date
Jul 1, 2017
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Feb 10, 2023

Study contacts

Guy Boeckxstaens, M.D.
principal investigator · Catholic University Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion